Dr. Mark M. Awad, MD, PhD
- Medicare services, 2024
- 219
- Medicare patients, 2024
- 106
- Part D claims, 2024
- 168
- Publications
- 159
- Clinical trials
- 8
- Practice address
- 1275 York Avenue, New York, NY 10065
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Awad's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Mark M. Awad is a medical oncologist in New York, New York
Dr. Awad practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.
Dr. Awad's NPI, 1831359355, was assigned on June 10, 2008. Dr. Awad graduated from The Johns Hopkins University School of Medicine in 2008. Dr. Awad holds New York license 333119.
- NPI
- 1831359355NPI Registry (opens in a new tab)
- Medicare PAC ID
- 0446418438
- NPI enumeration date
- June 10, 2008
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 44
- Medical school graduation
- 2008
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Mark M. Awad practices at Memorial Sloan Kettering Cancer Center in New York, New York
Dr. Awad's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.
- Memorial Sloan Kettering Cancer Center1275 York Avenue, New York, NY 10065
Source: Dmand AI Affiliation Data
Dr. Mark M. Awad is affiliated with 4 sites of care and 3 medical groups
Dr. Awad's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Awad to 3 more group practices and clinics and 2 medical groups, each named with a free account.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Mark M. Awad's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Awad practices, 4 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Memorial Sloan Kettering Cancer Center | Available with a free account |
| +3 more sites and 2 medical groups | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across Memorial Sloan Kettering Cancer Center and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Mark M. Awad is one of 458 medical oncologists in New York
Medical oncology is Dr. Awad's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Awad is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Awad's licenses on file in 6 states: New York, Florida, New Jersey, Massachusetts, New Hampshire and Rhode Island.
Specialties and state licenses
- Medical oncology, New YorkPrimary
- Florida license
- New Jersey license
- Massachusetts license
- New Hampshire license
- Rhode Island license
Clinical focus
Dmand AI lists breast cancer, chronic anemia, lung cancer and prostate cancer among the conditions Dr. Awad treats.
Medical oncologists near Dr. Awad
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Mark M. Awad billed Medicare for 219 services in 2024
CMS data shows 219 Medicare services from Dr. Awad across 4 procedure codes in 2024, for 106 Medicare patients. Medicare paid $21,162 for them.
Dr. Awad's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 4142024: 21947%
Where Dr. Awad's Medicare services took place, 2024
- In an office12758%
- In a facility9242%
Dr. Awad compared with the New York median for medical oncologists, 2024
- Dr. Awad
- New York median
- Medicare services
- 219vs 34036% below
- Medicare patients
- 106vs 1125% below
- Part D claims
- 82vs 13037% below
Medians across 421 medical oncologists in New York with Dmand AI profiles that report each measure.
Dr. Awad's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Awad?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Awad and other medical oncologists in New York.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Mark M. Awad treated 106 Medicare patients in 2024, average age 73
CMS counts 106 Medicare patients who saw Dr. Awad in 2024. The largest group is 75 to 84, with 46 patients. 75% of them have cancer, and 75% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Awad's median patient age at 74, with 56% women.
Dr. Awad's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Dr. Awad's Medicare patients by sex, 2024
- Women5855%
- Men4845%
Chronic conditions among Dr. Awad's Medicare patients, 2024
- Cancer75%
- High blood pressure75%
- High cholesterol75%
- Arthritis46%
- Anxiety44%
- COPD40%
- Ischemic heart disease39%
- Mood disorders32%
Share of Medicare patients with each condition. A patient can have several.
Dr. Awad's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 74
Patient panel by sex, all payers
- Women56%
- Men43%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Mark M. Awad wrote 168 Medicare Part D claims in 2024
In 2024, Dr. Awad wrote 168 Medicare Part D claims for 47 patients. 44% of them were for generic drugs. CMS names the drug for 82 of them, across 5 drugs with 11 or more claims each, at $549,824 in total drug cost. In 2023, CMS named 114 claims across 5 drugs.
Dr. Awad's Part D claims by kind of drug, 2024
- Generic74 claims44%
- Brand-name94 claims56%
Dr. Awad's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 1142024: 8228%
Drugs named by CMS: 5 in 2024, 5 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Mark M. Awad scored 84 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Awad for performance year 2024, reported as part of a group. Dr. Awad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Awad as offering telehealth.
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
Dr. Awad's MIPS scores, performance year 2024
- 84of 100Final score
- 65of 100Quality
- 100of 100Promoting Interoperability
- 40of 100Improvement Activities
- 69of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Mark M. Awad has 159 publications on record
Dmand AI links 159 papers to Dr. Awad, published from 2006 to 2025. 2020 was the busiest year, with 20. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Awad has published most often in Clin Cancer Res. Dr. Awad's most frequent co-authors are Biagio Ricciuti, Matthew D. Hellmann, MD and Victor Renault Vaz, MD.
Dr. Awad's papers by year, 2016 to 2025
Topics Dr. Awad writes about most
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Combined Chemotherapy Protocols
- B7-H1 Antigen
- Immune Checkpoint Inhibitors
- Immunotherapy
- Biomarkers, Tumor
- Antibodies, Monoclonal, Humanized
Dr. Awad's most frequent co-authors
- Biagio Ricciuti55 shared papers
- Matthew D. Hellmann, MD15 shared papers
- Victor Renault Vaz, MD14 shared papers
Recent publications by Dr. Awad
See who Dr. Awad researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Awad works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Mark M. Awad has worked on 8 clinical trials
Dmand AI links Dr. Awad to 8 clinical trials. 5 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Deafness, Autosomal Recessive 39. Dana-Farber Cancer Institute sponsors the most, 3. Open Payments lists research payments to Dr. Awad that name 2 trials.
Clinical trials with Dr. Awad by phase
- 1Phase 1: 1 trial
- 1Phase 1/2: 1 trial
- 1Phase 2: 1 trial
- 1Phase 3: 1 trial
- NonePhase 4: no trials
Conditions in Dr. Awad's trials
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Bronchogenic
- Deafness, Autosomal Recessive 39
- Mesothelioma
- Squamous Cell Carcinoma of Head and Neck
Investigators on the most trials with Dr. Awad
- Alexander Edward Dela Cruz Drilon, MD2 shared trials
- Jhanelle E. Gray, MD2 shared trials
- Mariam Alexander1 shared trial
Recent clinical trials with Dr. Awad
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer (opens in a new tab)
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Mark M. Awad received $258,445 in industry payments from 2016 to 2025
CMS Open Payments shows 204 general payments to Dr. Awad from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. Merck Sharp & Dohme Corporation paid the most, $65,892. It also lists 15 research payments totaling $45,059 from 2017 to 2024, naming 2 clinical trials.
General payments to Dr. Awad by program year, 2016 to 2025
General payments to Dr. Awad by kind, 2016 to 2025
- Consulting fees$193,03775%
- Travel and lodging$31,99312%
- Speaker and faculty fees$22,9949%
- Honoraria$6,5003%
- Other$3,9202%
Companies that paid Dr. Awad the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Mark M. Awad graduated from The Johns Hopkins University School of Medicine
Dr. Awad graduated from The Johns Hopkins University School of Medicine in 2008.
- Medical school
- Board certified in medical oncology
Source: Dmand AI Professional Profile Data
Dr. Mark M. Awad accepts plans from 7 insurance carriers
Dr. Awad is in network with 7 carriers, including Aetna, Excellus BlueCross BlueShield and Molina. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.
- Aetna
- Excellus BlueCross BlueShield
- Molina
- MVP Health Care
- CMS Medicare
- NY State Medicaid
- RI State Medicaid
Plan types Dr. Awad accepts, by number of carriers
- Medicare4
- EPO3
- Medicaid3
- PPO3
- HMO2
- POS1
Source: Dmand AI Insurance Network Data
Sources for Dr. Mark M. Awad's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| Insurance carriers and plan types | Dmand AI Insurance Network Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Mark M. Awad
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Mark M. Awad's NPI number?
Dr. Mark M. Awad's NPI number is 1831359355. It was assigned on June 10, 2008, and it is active in the NPI Registry.
What kind of doctor is Dr. Mark M. Awad?
Dr. Mark M. Awad is a medical oncologist in New York, New York. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Mark M. Awad practice?
Dr. Awad practices at 1275 York Avenue, New York, NY 10065. Dr. Awad's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Awad to 3 group practices and clinics and 2 medical groups.
What is Dr. Mark M. Awad's medical license number?
Dr. Awad holds New York license 333119, one of the licenses on file in 6 states.
Which states has Dr. Mark M. Awad been licensed in?
Dmand AI has state licenses on file for Dr. Awad in New York (2024 to 2026), Florida (since 2024), New Jersey (2024 to 2027), Massachusetts (2012 to 2025), New Hampshire (2024) and Rhode Island (2020).
Which hospitals is Dr. Mark M. Awad affiliated with?
Dr. Awad practices at Memorial Sloan Kettering Cancer Center in New York, New York.
What medical group is Dr. Mark M. Awad part of?
Dr. Awad is linked to Memorial Sloan Kettering Cancer Center. Dmand AI links Dr. Awad to 2 more medical groups.
Does Dr. Mark M. Awad accept Medicare?
Yes. CMS data shows Dr. Awad billed Medicare for 219 services in 2024, and Dr. Awad accepts Medicare assignment.
Does Dr. Mark M. Awad offer telehealth?
Yes. The CMS Doctors and Clinicians file lists Dr. Awad as offering telehealth services.
What is Dr. Mark M. Awad's MIPS score?
Dr. Awad's MIPS final score for performance year 2024 is 84 out of 100, reported as part of a group.
Show 10 more questionsShow fewer questions
How many Medicare patients does Dr. Mark M. Awad see?
CMS counts 106 Medicare patients who saw Dr. Awad in 2024, with an average age of 73.
Is Dr. Mark M. Awad board certified?
Yes. Dr. Awad is board certified in medical oncology by the American Board of Internal Medicine.
What services does Dr. Mark M. Awad bill to Medicare?
In 2024, Dr. Awad's most billed Medicare services were office visit, established patient (99215), office visit, established patient (99214) and hospital inpatient care (99232).
Where did Dr. Mark M. Awad go to medical school?
Dr. Awad graduated from The Johns Hopkins University School of Medicine in 2008.
What drugs does Dr. Mark M. Awad prescribe most?
In 2024 Medicare Part D data, Dr. Awad's most prescribed drugs by claims were Dexamethasone, Eliquis and Tagrisso.
Has Dr. Mark M. Awad received payments from drug or device companies?
CMS Open Payments shows $258,445 in general payments to Dr. Awad from 26 companies from 2016 to 2025. The largest total came from Merck Sharp & Dohme Corporation.
How long has Dr. Mark M. Awad been practicing?
Dr. Awad graduated from medical school in 2008, 18 years ago.
Does Dr. Mark M. Awad do research?
Dmand AI links 159 publications to Dr. Awad, published from 2006 to 2025. Dr. Awad has worked on 8 clinical trials.
Who does Dr. Mark M. Awad publish with?
Dr. Awad's most frequent co-authors are Biagio Ricciuti (55 shared papers), Matthew D. Hellmann, MD (15 shared papers) and Victor Renault Vaz, MD (14 shared papers).
What insurance does Dr. Mark M. Awad accept?
Dr. Awad is in network with 7 carriers, including Aetna, Excellus BlueCross BlueShield and Molina. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.
Selling to medical oncology practices?
See medical oncologists in New York by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card